U.S. approves Novartis cell therapy for lymphoma

(Reuters) - U.S. regulators approved Novartis' cell therapy Kymriah for treatment of patients with a second type of blood cancer, large B-cell lymphoma, that has worsened despite two or more earlier lines of therapy, the Swiss drugmaker said on Tuesday.

from Reuters: Health News https://ift.tt/2JIOHHG